Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
159989-65-8
Purity
95%
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in the treatment of HIV infection.
Properties
Name
Nelfinavir mesylate
Smiles
CC=1C(O)=CC=CC1C(=O)N[C@@H](CSC=2C=CC=CC2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C.CS(=O)(=O)O
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
Nelfinavir mesylate (CAS 159989-65-8), also known as PF-00346577, is a well-studied HIV protease inhibitor widely used in pharmacological and antiviral research. The compound has been extensively investigated for its ability to inhibit viral replication by targeting the HIV-1 protease enzyme. Due to its defined pharmacological profile, nelfinavir mesylate is frequently used as a reference molecule in antiviral screening programs and mechanistic studies.
The compound is characterized by a well-defined molecular formula and stable physicochemical properties that support reproducible experimental work. Researchers studying antiviral mechanisms often analyze the 159989-65-8 structure to better understand enzyme inhibition and structure-activity relationships. Laboratories working in pharmaceutical discovery or academic research may buy 159989-65-8 as a reliable compound for validating protease inhibition assays and evaluating new therapeutic candidates.
Nelfinavir mesylate is widely used in biomedical and antiviral research where inhibition of viral proteases plays a central role. The compound helps scientists explore molecular pathways involved in viral replication and host-virus interactions.
Researchers investigating protease inhibition frequently compare new compounds with established molecules such as PF-00346577 to evaluate potency and selectivity in experimental systems.
In vitro studies demonstrate that nelfinavir mesylate inhibits HIV-1 protease activity, thereby preventing the maturation of viral particles. This inhibition disrupts the cleavage of viral polyproteins, leading to the formation of non-infectious viral particles. Because of this mechanism, the compound is commonly used in biochemical assays designed to evaluate protease inhibition and antiviral activity.
Cell-based assays also use nelfinavir mesylate to study viral replication pathways and to test the effectiveness of newly synthesized antiviral compounds. Researchers often buy PF-00346577 for use as a benchmark molecule in comparative screening experiments.
In vivo research has shown that nelfinavir mesylate can reduce viral replication by blocking the proteolytic processing required for viral maturation. Studies using animal models help researchers understand how protease inhibitors affect viral load, pharmacokinetics, and systemic antiviral responses.
These investigations contribute to a broader understanding of antiviral therapy and support the development of improved inhibitors targeting viral enzymes.
The biochemical activity of nelfinavir mesylate is associated with its ability to bind the active site of HIV-1 protease. By inhibiting this enzyme, the compound prevents the cleavage of viral polyprotein precursors that are necessary for the formation of mature infectious virus particles.
Beyond its antiviral role, research has explored additional cellular effects of the compound, including its influence on protein processing pathways and intracellular signaling mechanisms. Such studies expand the potential relevance of protease inhibitors in broader biomedical research.
Nelfinavir mesylate is widely used in research laboratories due to its well-characterized pharmacological profile and reliable experimental performance.
High-quality bioactive compounds are essential for modern drug discovery programs. Research organizations working in pharmaceutical, biotechnology, and academic environments rely on reliable chemical suppliers to access validated molecules that support accurate screening and mechanistic investigations.
SDS
AG1343 | Viracept | nelfinavir mesylate
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$68
2 mg
$72
5 mg
$80
10 mg
$103
15 mg
$118
20 mg
$132
25 mg
$144
30 mg
$152
35 mg
$167
40 mg
$186
45 mg
$198
50 mg
$212
75 mg
$306
100 mg
$POA
Quantity
1
Total amount
$ 80
AG1343 | Viracept | nelfinavir mesylate
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.
CAS:159989-64-7
0